Last updated: March 21, 2026
What is the drug associated with NDC 65862-0952?
The National Drug Code (NDC) 65862-0952 corresponds to Atezolizumab (brand name Tecentriq). It is an immune checkpoint inhibitor used in the treatment of various cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), urothelial carcinoma, and triple-negative breast cancer (TNBC). It is a monoclonal antibody targeting PD-L1.
Market Overview
Indications and Patient Population
-
Primary indications:
- NSCLC (non-small cell lung cancer)
- SCLC (small cell lung cancer)
- Urothelial carcinoma
- TNBC (triple negative breast cancer)
-
Market size:
- The global oncology market was valued at approximately $165 billion in 2021 (IQVIA).
- Lung and breast cancer segments collectively account for roughly 40% of this market.
- Estimated eligible patient populations:
- NSCLC: ~225,000 annual new cases in the U.S. (American Cancer Society, 2022).
- SCLC: ~28,000 cases yearly in the U.S.
- Urothelial carcinoma: ~81,000 cases annually.
- TNBC: ~18,000 new cases in the U.S.
- The total addressable population for Atezolizumab in the U.S. approximates 350,000 patients annually.
Competitive Landscape
- Main competitors include:
- Pembrolizumab (Keytruda)
- Nivolumab (Opdivo)
- Durvalumab (Imfinzi)
- Market players are competing primarily on efficacy, approved indications, and pricing strategies.
Pricing Analysis
Current Pricing
- The average list price for a 1200 mg dose of Atezolizumab (Tecentriq) in the U.S. is approximately $12,000 per infusion.
- Typical treatment involves administration every 3 weeks, with an average of 17 doses per year.
Estimated Annual Costs
| Parameter |
Value |
| Cost per infusion |
$12,000 |
| Number of infusions per year |
17 |
| Annual treatment cost per patient |
$204,000 |
Reimbursement and Cost-Effectiveness
- Actual reimbursement prices vary by insurer and region.
- Cost-effectiveness analyses suggest a value-based price range of $150,000 - $200,000 per year, aligning with current market prices.
Price Projections
-
Short-term (1-2 years):
- Prices are likely to stay stable given the high drug efficacy, competitive pressure from biosimilars (if any), and payer reimbursement.
-
Medium-term (3-5 years):
- Introduction of biosimilar PD-L1 inhibitors could lead to price erosion, potentially reducing Atezolizumab’s price by 20-30%.
- Improved manufacturing efficiencies may also lower costs.
-
Long-term (5+ years):
- Price reductions may reach 40-50% if biosimilar competition or alternative therapies gain acceptance.
- Expansion into additional indications and combination regimens could maintain demand without significant price decreases.
Market Dynamics Influencing Pricing
- Regulatory approvals: Additional indications extend market life and revenue streams.
- Patent expirations: Patents for Tecentriq expire around 2029, opening competition.
- Market penetration strategies: Differential pricing in emerging markets could reduce global average prices.
- Reimbursement trends: Payers are increasingly favoring value-based contracts, which could influence net prices.
Summary of Key Data Points
| Aspect |
Data |
| Indications |
NSCLC, SCLC, urothelial carcinoma, TNBC |
| U.S. patient population |
Approx. 350,000 annually |
| Average treatment cost |
$204,000/year |
| Price per infusion |
~$12,000 |
| Competitive landscape |
Pembrolizumab, Nivolumab, Durvalumab |
| Patent expiry |
2029 |
Key Takeaways
- Atezolizumab remains a high-cost, high-value biologic with stable pricing in the short term.
- Growing indications and patient access will support revenue continuity.
- Biosimilar competition anticipated post-2029 will likely pressure prices downward.
- Cost reductions through manufacturing efficiencies and volume growth may moderate price declines.
- Market expansion into emerging territories could influence global price dynamics.
Frequently Asked Questions
1. How does Atezolizumab's pricing compare to similar PD-L1 inhibitors?
It typically costs around $12,000 per infusion, similar to Durvalumab but higher than some biosimilar competitors. Its annual treatment cost is approximately $204,000.
2. What factors could cause Atezolizumab's price to decrease?
Introduction of biosimilars after patent expiry, increased competition from other immunotherapies, and payer pressure for value-based pricing.
3. What is the potential impact of biosimilars on this market?
Biosimilars, expected post-2029, could reduce biologic prices by 20-50% once approved, assuming comparable efficacy and safety.
4. Are there opportunities for price optimization through combination therapies?
Yes. Combining Atezolizumab with chemotherapy or targeted agents could expand indications and justify premium pricing, but may also influence reimbursement strategies.
5. How do geographic differences affect pricing and market penetration?
Profiles vary significantly; in emerging markets, prices are lower due to purchasing power differences and negotiated discounts. Global pricing strategies will adapt accordingly.
Sources
[1] American Cancer Society. (2022). Cancer Statistics.
[2] IQVIA. (2022). Global Oncology Market Report.
[3] FDA. (2022). Drug Approvals and Patent Expiry Dates.
[4] Medicare. (2022). Reimbursement Policies for Oncology Drugs.
